KalshiVerificar disponibilidadeKYC obrigatório2% de taxaDados de resolução verificadosCalibração aproximadaProbabilidade implícita atualBefore September 24%-2.0%Líder entre 4 opções
Qualidade do mercado
80 / 100
Alta qualidadeVolume 24h
1,3 mil €
Liquidez
27,5 mil €
Alta liquidezCompra / Venda
24.0% / 25.0%
Spread
4.2%
Spread moderadoDados do mercado
Atualizado há 18 minutos
24/03/26, 14:001/09/26, 3:59
Tendências
Apenas fundos simulados, sem dinheiro realIsto não é aconselhamento financeiro
Resultado escolhido
Before September24%
Tendência de volume
$1.5k2 de jul.25d de dados26 de jul.
Mercados Relacionados
New pandemic in 2026?
6,2 mil €Sim: 7%
POLYMARKET
POLYMARKET
Measles cases in 2026?
2,5 mil €Above 4000: 39%KALSHI
KALSHI
Hantavirus pandemic in 2026?
2,2 mil €Sim: 3%POLYMARKET
POLYMARKET
Ebola pandemic in 2026?
1,7 mil €Sim: 4%POLYMARKET
POLYMARKET
When "Will Masking Return"? (widespread mask mandates in the USA)
996,3 €September 2023: 1%MANIFOLD MARKETS
MANIFOLD MARKETSWill the NIH indirect cost cap stick?
879,1 €Sim: 11.4%MANIFOLD MARKETS
MANIFOLD MARKETSAtivos nestes tópicos
Regras
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
- The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
- Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Nov 1, 2026, then the market resolves to Yes.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes.